PI3K/AKT/mTOR signaling pathway in breast cancer: from molecular landscape to clinical aspects

D Miricescu, A Totan, II Stanescu-Spinu… - International journal of …, 2020 - mdpi.com
Breast cancer is a serious health problem worldwide, representing the second cause of
death through malignancies among women in developed countries. Population …

[HTML][HTML] The crucial role of protein phosphorylation in cell signaling and its use as targeted therapy

F Ardito, M Giuliani, D Perrone… - International …, 2017 - spandidos-publications.com
Protein phosphorylation is an important cellular regulatory mechanism as many enzymes
and receptors are activated/deactivated by phosphorylation and dephosphorylation events …

PI3K/AKT/mTOR-targeted therapy for breast cancer

K Zhu, Y Wu, P He, Y Fan, X Zhong, H Zheng, T Luo - Cells, 2022 - mdpi.com
Phosphatidylinositol 3-kinase (PI3K), protein kinase B (PKB/AKT) and mechanistic target of
rapamycin (mTOR)(PAM) pathways play important roles in breast tumorigenesis and confer …

Comprehensive molecular portraits of human breast tumours

We analysed primary breast cancers by genomic DNA copy number arrays, DNA
methylation, exome sequencing, messenger RNA arrays, microRNA sequencing and …

Sequence analysis of mutations and translocations across breast cancer subtypes

S Banerji, K Cibulskis, C Rangel-Escareno, KK Brown… - Nature, 2012 - nature.com
Breast carcinoma is the leading cause of cancer-related mortality in women worldwide, with
an estimated 1.38 million new cases and 458,000 deaths in 2008 alone. This malignancy …

CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors

SR Vora, D Juric, N Kim, M Mino-Kenudson, T Huynh… - Cancer cell, 2014 - cell.com
Activation of the phosphoinositide 3-kinase (PI3K) pathway occurs frequently in breast
cancer. However, clinical results of single-agent PI3K inhibitors have been modest to date. A …

Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers

VWY Lui, ML Hedberg, H Li, BS Vangara, K Pendleton… - Cancer discovery, 2013 - AACR
Genomic findings underscore the heterogeneity of head and neck squamous cell carcinoma
(HNSCC). Identification of mutations that predict therapeutic response would be a major …

Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials

C Fritsch, A Huang, C Chatenay-Rivauday… - Molecular cancer …, 2014 - AACR
Somatic PIK3CA mutations are frequently found in solid tumors, raising the hypothesis that
selective inhibition of PI3Kα may have robust efficacy in PIK3CA-mutant cancers while …

Cancer development, progression, and therapy: an epigenetic overview

S Sarkar, G Horn, K Moulton, A Oza, S Byler… - International journal of …, 2013 - mdpi.com
Carcinogenesis involves uncontrolled cell growth, which follows the activation of oncogenes
and/or the deactivation of tumor suppression genes. Metastasis requires down-regulation of …

Drug resistance in colorectal cancer: from mechanism to clinic

Q Wang, X Shen, G Chen, J Du - Cancers, 2022 - mdpi.com
Simple Summary Chemotherapy, radiotherapy and molecularly targeted therapy could
improve the prognosis of colorectal cancer (CRC) patients. Recently, immunotherapy …